Advances and therapeutic opportunities in visual cycle modulation.

Area of Science:

• Biochemistry
• Ophthalmology
• Pharmacology

Background:

• The visual cycle regenerates 11-cis-retinal for continuous vision.
• Retinoid flux in the visual cycle contributes to retinal pathologies like Stargardt disease and AMD.
• Toxic intermediates accumulate, causing cellular damage and photoreceptor loss.

Purpose of the Study:

• To review current and emerging strategies for modulating the visual cycle.
• To examine drug discovery opportunities for retinal diseases linked to the visual cycle.
• To assess the efficacy and challenges of visual cycle modulators.

Main Methods:

• Comprehensive review of scientific literature on visual cycle modulators.
• Analysis of intrinsic (enzyme/protein targeting) and extrinsic (retinoid availability) strategies.
• Evaluation of preclinical and clinical study data for therapeutic agents.

Main Results:

• Multiple strategies targeting visual cycle enzymes, proteins, and receptors have emerged.
• Agents show promise in animal models, reducing pathology and improving retinal survival.
• Several modulators are in clinical trials, but none are FDA-approved yet.

Conclusions:

• Visual cycle modulation is a promising therapeutic avenue for retinal diseases.
• Optimizing drug specificity and minimizing side effects like nyctalopia are key challenges.
• Further drug discovery is needed for safe and effective vision preservation.